Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?
Yahoo Finance · Aug 3, 2026 · Apogee Therapeutics, Inc. Common Stock (APGE)
Apogee Therapeutics stock has delivered a very strong run over the past few years, yet the valuation checks currently lean expensive, which raises the question of how much of that optimism is already in the price. Apogee Therapeutics has returned roughly 5.5x over the past 3 years, which is a very large gain that can leave limited room if expectations ease. Expectations around the company’s ability to convert its pipeline into durable revenue streams can support the current share price. At...
Not investment advice. Cached headline, not a full reprint.